Demyelination in multiple sclerosis

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 89-99

  Lubetzki, Catherine ^a   Stankoff, Bruno ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adaptive immunity; Antibodies; Antigens; Autoimmunity; Cytokines; Inflammation; Injury; Innate immunity; Mechanisms; Myelin proteins; Neuronal damage; Oligodendrocytes

Indexed keywords

ANTIBODY; ANTIGEN; CYTOKINE; MYELIN PROTEIN; SODIUM CHANNEL;

ADAPTIVE IMMUNITY; ANIMAL; ARTICLE; AUTOIMMUNITY; CYTOLOGY; DEMYELINATING DISEASE; HUMAN; IMMUNOLOGY; INFLAMMATION; INJURY; INNATE IMMUNITY; MECHANISMS; METABOLISM; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBER; NEURONAL DAMAGE; OLIGODENDROCYTES; OLIGODENDROGLIA; PATHOLOGY;

ADAPTIVE IMMUNITY; ANTIBODIES; ANTIGENS; AUTOIMMUNITY; CYTOKINES; INFLAMMATION; INJURY; INNATE IMMUNITY; MECHANISMS; MYELIN PROTEINS; NEURONAL DAMAGE; OLIGODENDROCYTES;

ANIMALS; AXONS; DEMYELINATING DISEASES; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; SODIUM CHANNELS;

EID: 84893470089     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00004-2     Document Type: Chapter

References (133)

1. Akassoglou K., Bauer J., Kassiotis G., et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998, 153:801-813.
2. Archelos J.J., Hartung H.P. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 2000, 23:317-327.
3. Arnett H.A., Mason J., Marino M., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001, 4:1116-1122.
4. Arroyo E.J., Xu T., Grinspan J., et al. Genetic dysmyelination alters the molecular architecture of the nodal region. J Neurosci 2002, 22:1726-1737.
5. Babbe H., Roers A., Waisman A., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393-404.
6. Banki K., Colombo E., Sia F., et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 1994, 180:1649-1663.
7. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-468.
8. Barnett M.H., Parratt J.D., Cho E.S., et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009, 65:32-46.
9. Bennett V., Lambert S. Physiological roles of axonal ankyrins in survival of premyelinated axons and localization of voltage-gated sodium channels. J Neurocytol 1999, 28:303-318.
10. Berger J., Moser H.W., Forss-Petter S. Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol 2001, 14:305-312.
11. Berger T., Rubner P., Schautzer F., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
12. Beutler B. Innate immunity: an overview. Mol Immunol 2004, 40:845-859.
13. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
14. Black J.A., Dib-Hajj S., Baker D., et al. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 2000, 97:11598-11602.
15. Bostock H., Sears T.A. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J Physiol 1978, 280:273-301.
16. Boyle M.E., Berglund E.O., Murai K.K., et al. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 2001, 30:385-397.
17. Bradl M., Hohlfeld R. Molecular pathogenesis of neuroinflammation. J Neurol Neurosurg Psychiatry 2003, 74:1364-1370.
18. Brilot F., Dale R.C., Selter R.C., et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009, 66:833-842.
19. Butovsky O., Landa G., Kunis G., et al. Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J Clin Invest 2006, 116:905-915.
20. Campbell I.L. Structural and functional impact of the transgenic expression of cytokines in the CNS. Ann N Y Acad Sci 1998, 840:83-96.
21. Charles P., Hernandez M.P., Stankoff B., et al. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A 2000, 97:7585-7590.
22. Charles P., Tait S., Faivre-Sarrailh C., et al. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 2002, 12:217-220.
23. Chen X., Oppenheim J.J. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology 2011, 133:426-433.
24. Coman I., Aigrot M.S., Seilhean D., et al. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 2006, 129:3186-3195.
25. Corbin J.G., Kelly D., Rath E.M., et al. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 1996, 7:354-370.
26. Correale J., McMillan M., McCarthy K., et al. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology 1995, 45:1370-1378.
27. Craner M.J., Hains B.C., Lo A.C., et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004, 127:294-303.
28. 2+ exchanger. Proc Natl Acad Sci U S A 2004, 101:8168-8173. 25.
29. Croxford J.L., Anger H.A., Miller S.D. Viral delivery of an epitope from Haemophilus influenzae induces central nervous system autoimmune disease by molecular mimicry. J Immunol 2005, 174:907-917.
30. David S., Lacroix S. Molecular approaches to spinal cord repair. Annu Rev Neurosci 2003, 26:411-440.
31. Desmazières A., Sol-Foulon N., Lubetzki C. Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology?. Mult Scler 2012, 18:133-137.
32. Disanto G., Morahan J.M., Barnett M.H., et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012, 78:823-832.
33. Dupree J.L., Girault J.A., Popko B. Axo-glial interactions regulate the localization of axonal paranodal proteins. J Cell Biol 1999, 147:1145-1152.
34. Einheber S., Zanazzi G., Ching W., et al. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 1997, 139:1495-1506.
35. Fabriek B.O., Zwemmer J.N., Teunissen C.E., et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005, 161:190-194.
36. Gaertner S., de Graaf K.L., Greve B., et al. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004, 63:2381-2383.
37. Genain C.P., Cannella B., Hauser S.L., et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999, 5:170-175.
38. Greter M., Heppner F.L., Lemos M.P., et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005, 11:328-334.
39. Grigoriadis N., Hadjigeorgiou G.M. Virus-mediated autoimmunity in Multiple Sclerosis. J Autoimmune Dis 2006, 3:1.
40. Harauz G., Ishiyama N., Hill C.M., et al. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 2004, 35:503-542.
41. Hauser S.L., Bhan A.K., Gilles F., et al. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986, 19:578-587.
42. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
43. Hoftberger R., Aboul-Enein F., Brueck W., et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004, 14:43-50.
44. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14599-14606.
45. Horwitz M.S., Evans C.F., McGavern D.B., et al. Primary demyelination in transgenic mice expressing interferon-gamma. Nat Med 1997, 3:1037-1041.
46. Horwitz M.S., Bradley L.M., Harbertson J., et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998, 4:781-785.
47. Horwitz M.S., Evans C.F., Klier F.G., et al. Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules. Lab Invest 1999, 79:235-242.
48. Howell O., Palser A., Polito A., et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 2006, 129:3173-3185.
49. Huseby E.S., Liggitt D., Brabb T., et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001, 194:669-676.
50. Jacobsen M., Cepok S., Quak E., et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002, 125:538-550.
51. Jenkins S.M., Bennett V. Ankyrin-G coordinates assembly of the spectrin-based membrane skeleton, voltage-gated sodium channels, and L1 CAMs at Purkinje neuron initial segments. J Cell Biol 2001, 155:739-746.
52. Kappos L., Li D., Calabresi P.A., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
53. Karadottir R., Cavelier P., Bergersen L.H., et al. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438:1162-1166.
54. Kerlero de Rosbo N., Milo R., Lees M.B., et al. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993, 92:2602-2608.
55. Kim J.K., Mastronardi F.G., Wood D.D., et al. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2003, 2:453-462.
56. Kooi E.J., van Horssen J., Witte M.E., et al. Abundant extracellular myelin in the meninges of patients with multiple sclerosis. Neuropathol Appl Neurobiol 2009, 35:283-295.
57. Kornek B., Storch M.K., Bauer J., et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001, 124:1114-1124.
58. Kotter M.R., Zhao C., van Rooijen N., et al. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18:166-175.
59. Kovacs G.G., Hoftberger R., Majtenyi K., et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005, 128:35-41.
60. Krogsgaard M., Wucherpfennig K.W., Cannella B., et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 2000, 191:1395-1412.
61. Lalive P.H., Menge T., Delarasse C., et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:2280-2285.
62. Lampasona V., Franciotta D., Furlan R., et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004, 62:2092-2094.
63. Lampert P.W., Sims J.K., Kniazeff A.J. Mechanism of demyelination in JHM virus encephalomyelitis. Electron microscopic studies. Acta Neuropathol (Berl) 1973, 24:76-85.
64. Lang H.L., Jacobsen H., Ikemizu S., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002, 3:940-943.
65. Lassmann H. Recent neuropathological findings in MS - implications for diagnosis and therapy. J Neurol 2004, 251(Suppl 4):IV2-IV5.
66. Lehmann P.V., Sercarz E.E., Forsthuber T., et al. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993, 14:203-208.
67. Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465.
68. Linington C., Bradl M., Lassmann H., et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
69. Lipton H.L., Canto M.C. Theiler's virus-induced central nervous system disease in mice. UCLA Forum Med Sci 1976, 263-277.
70. Lucchinetti C., Bruck W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
71. Mantegazza R., Cristaldini P., Bernasconi P., et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 2004, 16:559-565.
72. Martin R., Howell M.D., Jaraquemada D., et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991, 173:19-24.
73. Mathey E.K., Derfuss T., Storch M.K., et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007, 204:2363-2372.
74. Mathis C., Denisenko-Nehrbass N., Girault J.A., et al. Essential role of oligodendrocytes in the formation and maintenance of central nervous system nodal regions. Development 2001, 128:4881-4890.
75. Matute C. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci U S A 1998, 95:10229-10234.
76. McDonald W.I. The effects of experimental demyelination on conduction in peripheral nerve: a histological and electrophysiological study. II. Electrophysiological observations. Brain 1963, 86:501-524.
77. McDonald J.W., Althomsons S.P., Hyrc K.L., et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998, 4:291-297.
78. McMahon E.J., Bailey S.L., Castenada C.V., et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005, 11:335-339.
79. Menegoz M., Gaspar P., Le Bert M., et al. Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron 1997, 19:319-331.
80. Micu I., Jiang Q., Coderre E., et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006, 439:988-992.
81. Miller S.D., Vanderlugt C.L., Begolka W.S., et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997, 3:1133-1136.
82. Moll C., Mourre C., Lazdunski M., et al. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 1991, 556:311-316.
83. Moscarello M.A., Wood D.D., Ackerley C., et al. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994, 94:146-154.
84. Moscarello M.A., Pritzker L., Mastronardi F.G., et al. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem 2002, 81:335-343.
85. Moser H.W. Adrenoleukodystropies. Myelin Biology and Disorders 2004, 807-839. Elsevier Academic Press, Amsterdam. R.A. Lazzarini, J.W. Griffin, H. Lassmann (Eds.).
86. Musse A.A., Boggs J.M., Harauz G. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci U S A 2006, 103:4422-4427.
87. Neumann H., Medana I.M., Bauer J., et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002, 25:313-319.
88. Noebels J.L., Marcom P.K., Jalilian-Tehrani M.H. Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature 1991, 352:431-434.
89. Oldstone M.B. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol 2005, 296:1-17.
90. Ota K., Matsui M., Milford E.L., et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346:183-187.
91. Owens G.P., Bennett J.L. Trigger, pathogen, or bystander: the complex nexus linking Epstein-Barr virus and multiple sclerosis. Mult Scler 2012, 18:1204-1208.
92. Owens T., Wekerle H., Antel J. Genetic models for CNS inflammation. Nat Med 2001, 7:161-166.
93. Panitch H.S., Hirsch R.L., Haley A.S., et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
94. Pitt D., Nagelmeier I.E., Wilson H.C., et al. Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 2003, 61:1113-1120.
95. + channels. Neuron 1999, 24:1037-1047.
96. Poliak S., Gollan L., Salomon D., et al. Localization of Caspr2 in myelinated nerves depends on axon-glia interactions and the generation of barriers along the axon. J Neurosci 2001, 21:7568-7575.
97. Powell H.C., Lampert P.W. Oligodendrocytes and their myelin-plasma membrane connections in JHM mouse hepatitis virus encephalomyelitis. Lab Invest 1975, 33:440-445.
98. Prat A., Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005, 18:225-230.
99. Prineas J.W., Graham J.S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981, 10:149-158.
100. Prinz M., Garbe F., Schmidt H., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006, 116:456-464.
101. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997, 120:2149-2157.
102. Redwine L.S., Altemus M., Leong Y.M., et al. Lymphocyte responses to stress in postpartum women: relationship to vagal tone. Psychoneuroendocrinology 2001, 26:241-251.
103. Renno T., Taupin V., Bourbonniere L., et al. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci 1998, 12:376-389.
104. Ridsdale R.A., Beniac D.R., Tompkins T.A., et al. Three-dimensional structure of myelin basic protein. II. Molecular modeling and considerations of predicted structures in multiple sclerosis. J Biol Chem 1997, 272:4269-4275.
105. Rios J.C., Melendez-Vasquez C.V., Einheber S., et al. Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 2000, 20:8354-8364.
106. Salter M.G., Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005, 438:1167-1171.
107. Schlitt B.P., Felrice M., Jelachich M.L., et al. Apoptotic cells, including macrophages, are prominent in Theiler's virus-induced inflammatory, demyelinating lesions. J Virol 2003, 77:4383-4388.
108. Segal B.M., Constantinescu C.S., Raychaudhuri A., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796-804.
109. Shields S.D., Cheng X., Gasser A., et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012, 71:186-194.
110. Shrager P., Rubinstein C.T. Optical measurement of conduction in single demyelinated axons. J Gen Physiol 1990, 95:867-889.
111. Skulina C., Schmidt S., Dornmair K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004, 101:2428-2433.
112. Smith K.J. Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye 1994, 8:224-237.
113. Smith K.J., Hall S.M. Nerve conduction during peripheral demyelination and remyelination. J Neurol Sci 1980, 48:201-219.
114. Smith K.J., McDonald W.I. Spontaneous and evoked electrical discharges from a central demyelinating lesion. J Neurol Sci 1982, 55:39-47.
115. Smith K.J., Blakemore W.F., McDonald W.I. The restoration of conduction by central remyelination. Brain 1981, 104:383-404.
116. Smith K.J., Bostock H., Hall S.M. Saltatory conduction precedes remyelination in axons demyelinated with lysophosphatidyl choline. J Neurol Sci 1982, 54:13-31.
117. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-945.
118. Srivastava R., Aslam M., Kalluri S.R., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
119. Sun J.B., Olsson T., Wang W.Z., et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991, 21:1461-1468.
120. Sun D., Whitaker J.N., Huang Z., et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001, 166:7579-7587.
121. Traka M., Dupree J.L., Popko B., et al. The neuronal adhesion protein TAG-1 is expressed by Schwann cells and oligodendrocytes and is localized to the juxtaparanodal region of myelinated fibers. J Neurosci 2002, 22:3016-3024.
122. Traka M., Goutebroze L., Denisenko N., et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol 2003, 162:1161-1172.
123. Traugott U., Reinherz E.L., Raine C.S. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983, 219:308-310.
124. Turnley A.M., Miller J.F., Bartlett P.F. Regulation of MHC molecules on MBP positive oligodendrocytes in mice by IFN-gamma and TNF-alpha. Neurosci Lett 1991, 123:45-48.
125. van Noort J.M., van Sechel A.C., Bajramovic J.J., et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995, 375:798-801.
126. Walsh M.J., Tourtellotte W.W. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986, 163:41-53.
127. + channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 2004, 25:584-591.
128. Werner P., Pitt D., Raine C.S. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180.
129. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., et al. Lancet Neurol 2007, 6:805-815.
130. Wolswijk G., Balesar R. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain 2003, 126:1638-1649.
131. Wood D.D., Bilbao J.M., O'Connors P., et al. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996, 40:18-24.
132. Zhang Y., Burger D., Saruhan G., et al. The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis. Neurology 1993, 43:403-407.
133. Zhang H., Bennett J.L., Verkman A.S. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011, 70:943-954.